Research programme: RSV fusion inhibitors - Johnson and Johnson/Tibotec

Drug Profile

Research programme: RSV fusion inhibitors - Johnson and Johnson/Tibotec

Alternative Names: TMC-353121

Latest Information Update: 10 Aug 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development; Tibotec BVBA
  • Developer Janssen Research & Development
  • Class
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 03 Oct 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC-2007) added to the Pharmacokinetics and Viral Infections pharmacodynamics sections
  • 03 Oct 2006 Preclinical development for Respiratory syncytial virus infections in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top